Breztri can cost $400 or more without insurance, but Medicare may cover inhaler drugs for COPD, including Breztri. That said, the specific coverage and costs vary based on your exact plan. Breztri ...
AstraZeneca’s fixed-dose triple-combination therapy BREZTRI Aerosphere ® (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6μg) has been approved in ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
If you have chronic obstructive pulmonary disease (COPD)—an umbrella term for several lung diseases, including emphysema, chronic bronchitis and some forms of asthmatic bronchitis—you know what a game ...
The system is designed to help with treatment adherence by tracking medication use and reminding patients if a dose is missed. Airsupra is indicated for the as-needed treatment or prevention of ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled ...
With data from a second phase 3 trial, AstraZeneca has finally convinced FDA regulators that its new COPD offering deserves a place on the U.S. market just as a competitor from GlaxoSmithKline does.
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRIin patients with uncontrolled asthma published in The Lancet Respiratory Medicine Full results from the ...
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results